OBJECTIVES: The authors had for objective to assess the activity of a wide panel of antibiotics on extended-spectrum-β-lactamase producing Escherichia coli isolates (ESBL-Ec), because of the sharp increase of their frequency, leading to an increased use of carbapenems. MATERIAL AND METHODS: We selected 100 ESBL-Ec in which ESBLs were identified by PCR and sequencing, between 2009 and 2010. We determined the MICs of amoxicillin-clavulanate, piperacillin-tazobactam, temocillin, mecillinam, cefoxitin, cefotaxime, ceftazidime, aztreonam, tigecycline, nitrofurantoin, and fosfomycin using reference methods. The susceptibility profiles were defined according to EUCAST 2012 recommendations. RESULTS: Fosfomycin, nitrofurantoin, and pivmecillinam were active against more than 90% of isolates and remain excellent choices for the oral treatment of urinary tract infections (UTIs). Temocillin and piperacillin-tazobactam are also good candidates for the treatment of pyelonephritis or bloodstream infections. Only 27, 23, and 8% of isolates were susceptible to ceftazidime, cefepime, and cefotaxime, respectively. CONCLUSION: Our study results prove that in many cases, there are non-carbapenem alternatives for the treatment of ESBL-Ec infections.
OBJECTIVES: The authors had for objective to assess the activity of a wide panel of antibiotics on extended-spectrum-β-lactamase producing Escherichia coli isolates (ESBL-Ec), because of the sharp increase of their frequency, leading to an increased use of carbapenems. MATERIAL AND METHODS: We selected 100 ESBL-Ec in which ESBLs were identified by PCR and sequencing, between 2009 and 2010. We determined the MICs of amoxicillin-clavulanate, piperacillin-tazobactam, temocillin, mecillinam, cefoxitin, cefotaxime, ceftazidime, aztreonam, tigecycline, nitrofurantoin, and fosfomycin using reference methods. The susceptibility profiles were defined according to EUCAST 2012 recommendations. RESULTS:Fosfomycin, nitrofurantoin, and pivmecillinam were active against more than 90% of isolates and remain excellent choices for the oral treatment of urinary tract infections (UTIs). Temocillin and piperacillin-tazobactam are also good candidates for the treatment of pyelonephritis or bloodstream infections. Only 27, 23, and 8% of isolates were susceptible to ceftazidime, cefepime, and cefotaxime, respectively. CONCLUSION: Our study results prove that in many cases, there are non-carbapenem alternatives for the treatment of ESBL-Ec infections.
Authors: B A Cunha; C B Cunha; B Lam; J Giuga; J Chin; V F Zafonte; S Gerson Journal: Eur J Clin Microbiol Infect Dis Date: 2017-02-02 Impact factor: 3.267
Authors: C Putensen; B Ellger; S G Sakka; A Weyland; K Schmidt; M Zoller; N Weiler; D Kindgen-Milles; U Jaschinski; J Weile; S Lindau; M Kieninger; A Faltlhauser; N Jung; P Teschendorf; M Adamzik; M Gründling; T Wahlers; H Gerlach; F-A Litty Journal: Infection Date: 2019-06-12 Impact factor: 3.553
Authors: H Guet-Revillet; A Emirian; M Groh; B Nebbad-Lechani; E Weiss; O Join-Lambert; E Bille; V Jullien; J R Zahar Journal: Antimicrob Agents Chemother Date: 2014-04-28 Impact factor: 5.191
Authors: B Rossi; J F Soubirou; F Chau; L Massias; S Dion; R Lepeule; B Fantin; A Lefort Journal: Antimicrob Agents Chemother Date: 2015-11-02 Impact factor: 5.191
Authors: Brian D Johnston; Paul Thuras; Stephen B Porter; Connie Clabots; James R Johnson Journal: Eur J Clin Microbiol Infect Dis Date: 2021-04-23 Impact factor: 5.103
Authors: Catrin E Moore; Soeng Sona; Sar Poda; Hor Putchhat; Varun Kumar; Sun Sopheary; Nicole Stoesser; Rachel Bousfield; Nicholas Day; Christopher M Parry Journal: Paediatr Int Child Health Date: 2016-05 Impact factor: 1.990